MX2016010134A - Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo. - Google Patents
Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo.Info
- Publication number
- MX2016010134A MX2016010134A MX2016010134A MX2016010134A MX2016010134A MX 2016010134 A MX2016010134 A MX 2016010134A MX 2016010134 A MX2016010134 A MX 2016010134A MX 2016010134 A MX2016010134 A MX 2016010134A MX 2016010134 A MX2016010134 A MX 2016010134A
- Authority
- MX
- Mexico
- Prior art keywords
- axl
- cancer
- medicinal composition
- another embodiment
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000004480 active ingredient Substances 0.000 title abstract 2
- -1 heterocyclic carboxamide compound Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 230000004913 activation Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
[Problema] Proveer una composición farmacéutica para tratar cáncer relacionado con AXL, en otro aspecto, una composición farmacéutica para tratar cáncer con expresión elevada de AXL, e incluso en otro aspecto, una composición farmacéutica para tratar cáncer que tiene resistencia adquirida por la activación de AXL contra la terapia con un agente anticáncer. [Solución] Los presentes inventores han estudiado compuestos que tienen una acción inhibidora de AXL, y han encontrado que compuestos de diaminocarboxamida heterocíclica específicos tienen una acción inhibidora de AXL, y que las composiciones farmacéuticas que comprenden estos compuestos como un ingrediente activo tienen un efecto terapéutico sobre cáncer relacionado con AXL, en otro aspecto, cáncer con expresión elevada de AXL, e incluso en otro aspecto, cáncer que tiene resistencia adquirida por la activación de AXL contra la terapia con un agente anticáncer, con lo cual se completa la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010134A true MX2016010134A (es) | 2016-10-07 |
| MX363543B MX363543B (es) | 2019-03-27 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010134A MX363543B (es) | 2014-02-04 | 2015-02-03 | Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (es) |
| EP (1) | EP3103453B1 (es) |
| JP (1) | JP6390626B2 (es) |
| KR (1) | KR102322338B1 (es) |
| CN (3) | CN113425727A (es) |
| AU (1) | AU2015215578B2 (es) |
| BR (1) | BR112016017897A8 (es) |
| CA (1) | CA2938818C (es) |
| CY (1) | CY1122968T1 (es) |
| DK (1) | DK3103453T3 (es) |
| EA (1) | EA033304B1 (es) |
| ES (1) | ES2788390T3 (es) |
| HR (1) | HRP20200662T1 (es) |
| HU (1) | HUE049437T2 (es) |
| IL (1) | IL247077B (es) |
| LT (1) | LT3103453T (es) |
| ME (1) | ME03775B (es) |
| MX (1) | MX363543B (es) |
| MY (1) | MY193536A (es) |
| PH (1) | PH12016501527B1 (es) |
| PL (1) | PL3103453T3 (es) |
| PT (1) | PT3103453T (es) |
| RS (1) | RS60150B1 (es) |
| SG (1) | SG11201606413RA (es) |
| SI (1) | SI3103453T1 (es) |
| SM (1) | SMT202000214T1 (es) |
| TW (1) | TWI655945B (es) |
| UA (1) | UA120607C2 (es) |
| WO (1) | WO2015119122A1 (es) |
| ZA (1) | ZA201605379B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3103453B1 (en) * | 2014-02-04 | 2020-04-01 | Astellas Pharma Inc. | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| SI3318259T1 (sl) * | 2015-07-03 | 2023-06-30 | Astellas Pharma Inc. | Stabilni farmacevtski sestavki za oralno dajanje |
| JP6859954B2 (ja) * | 2015-11-04 | 2021-04-14 | アステラス製薬株式会社 | ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JPWO2022220227A1 (es) * | 2021-04-14 | 2022-10-20 | ||
| EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102446A2 (en) * | 2008-02-12 | 2009-08-20 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| JP5628145B2 (ja) * | 2008-03-19 | 2014-11-19 | ケムブリッジ・コーポレーション | 新規チロシンキナーゼ阻害剤 |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| SI3009428T1 (en) * | 2009-05-08 | 2018-04-30 | Astellas Pharma Inc. | DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS |
| CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112014012155A2 (pt) * | 2011-11-21 | 2017-05-30 | Immunogen Inc | método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| ES2700231T3 (es) * | 2012-11-21 | 2019-02-14 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| EP3103453B1 (en) * | 2014-02-04 | 2020-04-01 | Astellas Pharma Inc. | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| SI3318259T1 (sl) * | 2015-07-03 | 2023-06-30 | Astellas Pharma Inc. | Stabilni farmacevtski sestavki za oralno dajanje |
-
2015
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2015-02-03 SM SM20200214T patent/SMT202000214T1/it unknown
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt not_active Application Discontinuation
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja not_active Ceased
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active Active
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527B1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| ZA201603342B (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| TW201613901A (en) | New compounds | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
| TW201613578A (en) | Pharmaceutical combinations | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| MX2018014136A (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor. | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. | |
| HK1233917A1 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| MX2018004776A (es) | Compuestos oxaazaespiricos con actividad contral el dolor. | |
| HK1229709A1 (en) | Combination therapy for treating cancer |